Charles J. Homcy Sells 20,000 Shares of BridgeBio Pharma (NASDAQ:BBIO) Stock

BridgeBio Pharma (NASDAQ:BBIO) Chairman Charles J. Homcy sold 20,000 shares of BridgeBio Pharma stock in a transaction on Monday, February 10th. The shares were sold at an average price of $36.00, for a total value of $720,000.00. Following the completion of the transaction, the chairman now directly owns 1,342,291 shares of the company’s stock, valued at $48,322,476. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Charles J. Homcy also recently made the following trade(s):

  • On Tuesday, January 14th, Charles J. Homcy sold 10,000 shares of BridgeBio Pharma stock. The shares were sold at an average price of $35.00, for a total value of $350,000.00.

Shares of NASDAQ:BBIO opened at $34.65 on Friday. The company’s 50 day simple moving average is $34.48 and its 200 day simple moving average is $29.23. The company has a debt-to-equity ratio of 0.14, a current ratio of 14.00 and a quick ratio of 14.00. BridgeBio Pharma has a 1 year low of $17.61 and a 1 year high of $48.36.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. State Street Corp acquired a new stake in BridgeBio Pharma in the third quarter valued at about $7,550,000. California State Teachers Retirement System acquired a new position in BridgeBio Pharma during the 3rd quarter worth approximately $756,000. BlackRock Inc. acquired a new position in BridgeBio Pharma during the 2nd quarter worth approximately $1,442,000. TimesSquare Capital Management LLC increased its position in BridgeBio Pharma by 258.9% during the 3rd quarter. TimesSquare Capital Management LLC now owns 538,330 shares of the company’s stock worth $11,558,000 after purchasing an additional 388,330 shares in the last quarter. Finally, Metropolitan Life Insurance Co NY bought a new position in BridgeBio Pharma in the 3rd quarter valued at approximately $233,000. Institutional investors and hedge funds own 83.49% of the company’s stock.

BBIO has been the topic of several analyst reports. Raymond James increased their target price on BridgeBio Pharma from to in a report on Tuesday, January 7th. Piper Jaffray Companies dropped coverage on BridgeBio Pharma in a research note on Friday, October 18th. Zacks Investment Research raised BridgeBio Pharma from a “sell” rating to a “hold” rating in a research note on Monday, January 6th. Finally, UBS Group assumed coverage on shares of BridgeBio Pharma in a research report on Tuesday, December 3rd. They set a “reduce” rating for the company. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $40.63.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc finds, develops, and delivers various medicines for genetic diseases. The company has a pipeline of 15 development programs that include product candidates ranging from early discovery to late-stage development in various therapeutic areas, including genetic dermatology, oncology, cardiology, neurology, endocrinology, renal disease, and ophthalmology.

Recommended Story: How is the discount rate different from the Federal Funds rate?

Insider Buying and Selling by Quarter for BridgeBio Pharma (NASDAQ:BBIO)

Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.